share_log

Guardant Health, ConcertAI Collaborate On Agreement That Allows Biopharmaceutical Companies To Access The First Multi-Modal Real-World Data That Integrates Comprehensive Patient Electronic Medical Record Data With Both Genomic And Epigenomic Tumor...

Benzinga ·  Jan 16 13:15

Guardant Health, ConcertAI Collaborate On Agreement That Allows Biopharmaceutical Companies To Access The First Multi-Modal Real-World Data That Integrates Comprehensive Patient Electronic Medical Record Data With Both Genomic And Epigenomic Tumor Profiling Information Across The Continuum Of Cancer Care

  • Collaboration enables insights from ConcertAI national database of 5.5M clinical records and Guardant profiling data across 60+ tumor types
  • Longitudinal DNA methylation measurements and comprehensive genomic profiling allow deeper insights into intrinsic and acquired resistance mechanisms

Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, and ConcertAI, a leading oncology real-world evidence data and AI SaaS technology company, today announced a collaboration agreement that allows biopharmaceutical companies to access the first multi-modal real-world data (RWD) that integrates comprehensive patient electronic medical record (EMR) data with both genomic and epigenomic tumor profiling information across the continuum of cancer care.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 427

Recommended

Write a comment